• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis welcomes Professor Stephen Smith as new Chairman
Share
News

ProAxsis welcomes Professor Stephen Smith as new Chairman

October 25, 2019
-
Posted by David Ribeiro

ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman of the company’s Board of Directors with immediate effect.

Stephen has held senior leadership roles in the NHS and academia, including with the University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust.

He was responsible for the largest merger in the NHS, the creation of the UK’s first Academic Health Science Centre in 2007. The merger brought together four London based NHS Trusts and ultimately led to the creation of Imperial College Healthcare NHS Trust, where Stephen served for four years as the first CEO. He also retained his position as Dean of the Faculty of Medicine at Imperial College, London and was responsible for facilitating the commercialisation of life sciences and healthcare.

During his career, Stephen has spun two companies out of Cambridge – Metris Therapeutics Ltd and GNI Group Ltd. GNI was established as a start up in Japan in 2001 and successfully achieved an Initial Public Offering (IPO) on the Tokyo Stock Exchange six years later.

Stephen has extensive leadership experience, having served on the Boards of the National Healthcare Group in Singapore, the Royal Melbourne Hospital, and the Victorian Comprehensive Cancer Centre, a $1billion project to create a fully integrated cancer care facility that brings together an integrated research, service and education offering to four million patients in Victoria.

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “We’re delighted to welcome Professor Smith as the new Chairman of the Board of Directors, and believe that his vast experience in both healthcare and business will be a major asset to ProAxsis at this critical time for the company, as we seek to maximise the commercialisation of our product portfolio following the recent publication of new data for our neutrophil elastase point-of-care test.”

October 25, 2019

Related News

Other posts that you should not miss.
Announcements, NEATstik®, News

New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases

June 3, 2019
-
Posted by Webmaster

Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the …

Read More
June 3, 2019
Posted by Webmaster
Announcements, News, Trials

ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

June 19, 2017
-
Posted by Webmaster

ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the …

Read More
June 19, 2017
Posted by Webmaster
News

ProAxsis enhances portfolio with new CE Marked Immunoassay

August 2, 2018
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers …

Read More
August 2, 2018
Posted by David Ribeiro
← PREVIOUS POST
ProAxsis supports next generation of scientists
NEXT POST →
New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited appoints first distributor for DACH region
    December 14, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …

  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • February 21, 2021
    ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
  • December 14, 2020
    ProAxsis Limited appoints first distributor for DACH region
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
124 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
124 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
145 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
165 days ago
- ProAxsis
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis welcomes Professor Stephen Smith as new Chairman | ProAxsis